Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability t
Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
